Avenzoar Pharmaceuticals, Inc. — Form D
Avenzoar Pharmaceuticals, Inc. of Los Angeles, CA, a company, filed a Form D exempt-offering notice with the SEC on 2023-06-16. The offering totals $3.0M, of which $900K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-06-16
- Form: D
- Accession: 0001792612-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $900K
- Remaining: $2.1M
- Investors: 2
- Date of first sale: 2023-05-31
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-484484
Issuer
- Name: Avenzoar Pharmaceuticals, Inc.
- CIK: 0001792612
- Entity type: Corporation
- Jurisdiction: CALIFORNIA
- Incorporated: 2015
- Address: 1819 Outpost Dr., Los Angeles, CA, 90089
- Phone: (310) 502-0770
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Terrance J Bruggeman | Director | Los Angeles, CA |
| Mark J Chin | Director | Los Angeles, CA |
| Mouad J Edderkaoui | Director | Los Angeles, CA |
| Stephen J Pandol | Director | Los Angeles, CA |
| Shierley J Widjaja | Director | Los Angeles, CA |
| Terrance J Bruggeman | Executive Officer | Los Angeles, CA |
| David Kramer | Executive Officer | Herndon, VA |
| Terrance Bruggeman | Director | Encinitas, CA |
| Terrance Bruggeman | Executive Officer | Encinitas, CA |
| Mouad Edderkaoui | Director | Encinitas, CA |
| William Reavey | Executive Officer | Encinitas, CA |
Other filings by this issuer (1)
More